<DOC>
<DOCNO>EP-0651644</DOCNO> 
<TEXT>
<INVENTION-TITLE>
OVULATION INHIBITOR FOR HORMONAL CONTRACEPTION.
</INVENTION-TITLE>
<CLASSIFICATIONS>A61K31565	A61K31565	A61K3157	A61K3157	A61P1500	A61P1500	</CLASSIFICATIONS>
<CLASSIFICATIONS-THIRD>A61K	A61K	A61K	A61K	A61P	A61P	</CLASSIFICATIONS-THIRD>
<CLASSIFICATIONS-FOURTH>A61K31	A61K31	A61K31	A61K31	A61P15	A61P15	</CLASSIFICATIONS-FOURTH>
<ABSTRACT>
An ovulation inhibitor for hormonal contraception has two hormonal components separately arranged in a packaging unit for successive oral administration. Each hormonal component consists of a number of separately arranged hormonal daily units which can be individually taken from the packaging unit. One hormonal component (estrogen component) contains as hormonal active substance almost exclusively an estrogen preparation which prevents the follicle from ripening and the other hormonal component (estrogen-gestagen component) contains an estrogen preparation combined with a dose of a gestagen preparation at least sufficient for inhibiting ovulation. The ovulation inhibitor is characterized in that it has one or more estrogen components in 5 to 14 daily units that alternate with one or more estrogen-gestagen components in 23 to 14 daily units. The number of estrogen components is smaller than the number of daily units of estrogen-gestagen components. In the case where ethinyl estradiol is used as estrogen preparation, the dose of ethinyl estradiol per daily unit amounts to maximum 30(my)g.
</ABSTRACT>
<APPLICANTS>
<APPLICANT-NAME>
EHRLICH MARIKA DR MED
</APPLICANT-NAME>
<APPLICANT-NAME>
KUHL HERBERT PROF DR
</APPLICANT-NAME>
<APPLICANT-NAME>
EHRLICH, MARIKA, DR. MED.
</APPLICANT-NAME>
<APPLICANT-NAME>
KUHL, HERBERT, PROF. DR.
</APPLICANT-NAME>
</APPLICANTS>
<INVENTORS>
<INVENTOR-NAME>
EHRLICH MARIKA DR MED
</INVENTOR-NAME>
<INVENTOR-NAME>
KUHL HERBERT PROF DR
</INVENTOR-NAME>
<INVENTOR-NAME>
EHRLICH, MARIKA, DR. MED.
</INVENTOR-NAME>
<INVENTOR-NAME>
KUHL, HERBERT, PROF. DR.
</INVENTOR-NAME>
</INVENTORS>
</TEXT>
</DOC>
